← Search & browse all drugs

triamcinolone

S01BA05

Forms & Strengths

Intravitreal suspension: 40 mg/mL
Intravitreal implant: 0.18 mg
Injectable suspension (acetonide): 40 mg/mL
Topical cream/ointment: 0.025%, 0.1%, 0.5%
Oral paste: 0.1%

Adult Dosing

Posterior uveitis / Ophthalmic inflammation: 1 mg to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) injected intravitreally
Intravitreal implant: 1 implant inserted into the back of the affected eye
Intra-articular/Intramuscular: 2.5 mg to 60 mg depending on the site and severity, repeated as needed

Pediatric Dosing

Ophthalmic indications: Safety and efficacy have not been established in pediatric patients
Systemic/Local use: Dosing is individualized based on disease severity and body weight rather than strict age formulas

Indications

Visualization during vitrectomy (preservative-free formulations)
Macular edema following retinal vein occlusion
Noninfectious uveitis involving the posterior segment of the eye
Inflammatory skin conditions responsive to corticosteroids

Mechanism of Action

Synthetic fluorinated corticosteroid with potent anti-inflammatory, immunosuppressive, and antiproliferative properties
Binds to cytosolic glucocorticoid receptors, translocating into the nucleus to suppress pro-inflammatory cytokine expression and inhibit leukocyte infiltration

Contraindications

Active or suspected ocular or periocular bacterial, viral, or fungal infections
Keratitis caused by Herpes simplex
Known hypersensitivity to triamcinolone or any component of the formulation

Adverse Reactions

Increased intraocular pressure
Cataract formation (posterior subcapsular)
Endophthalmitis (post-intravitreal injection)
Visual disturbance and transient blurred vision
Retinal detachment

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat) may increase systemic corticosteroid exposure and risk of systemic side effects
Anticholinergic agents may lead to additive increases in intraocular pressure
Fluoroquinolones may have an increased risk of tendon rupture when used concurrently with systemic corticosteroids

Curated Content: Needs Vetting Before Put to Clinical Use